Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 383112
SancusoÂ® is the only skin patch approved by the U.S. Food and Drug Administration for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the SancusoÂ® patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patientâ€™s bloodstream. It can be worn for up to seven days in a row for chemotherapy regimens of up to five consecutive days.
IPSCIO Record ID: 243661
Licensor grants the right to use the Clinical Information and Data generated by or on behalf of Licensor and its Affiliates for the purpose of obtaining Regulatory Approval of the Licensed Product in the Territory.
Licensed Product shall mean a formulation of the Active Ingredient with the Biochronomer formulation, including the formulation designated by APP as APF530.
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and Radiotherapy.
The Field shall mean any and all human applications.
APF530 is currently in Phase 3 trials in the U.S. for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
IPSCIO Record ID: 222534
The Licensed Product means any product comprising, incorporating or containing any Compound, or an alternate form of any Compound, including, but not limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of any Compound to the extent such alternate form is claimed in the Licensor Patent Rights.
Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management of nausea and vomiting experienced by cancer patients undergoing treatment with emetogenic chemotherapy. Phase II clinical testing of rolapitant for the prevention of nausea and vomiting in cancer patients treated with highly emetogenic chemotherapy demonstrated promising five-day activity following the administration of a single dose.
IPSCIO Record ID: 8626
Technology licensed by a U.S. company to a U.S. company is an Oral Spray, which aims to prevent nausea and vomiting associated with chemotherapy and radiotherapy, as well as postoperative-induced nausea and vomiting. FDA recently agreed to review application for the spray. Note that the lower range of the royalty rate is estimated.
'Licensed Technology' shall mean the Licensor's Patents, the Licensor Know-How and the Drug Master File, collectively, but only with respect to the Exploitation of the Licensed Product.
'Licensed Product(s)' shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, overthe-counter or any other method for human application only that contains ondansetron delivered by means of the Licensed Process.
Ondansetron lingual spray , or â€œOLS,â€ our most recently-acquired product candidate,is a novel delivery system that utilizes the vast and highly-absorptive surfaces of the oral cavity (including the area under the tongue) to deliver the drug ondansetron, the most widely used drug to prevent chemotherapy-induced nausea and vomiting , directly into the bloodstream. Administration of ondansetron lingual spray (i.e., spraying on the tongue) will potentially decrease the time necessary to ahcive effective concentrations in the bloodstream, which we believe will more rapidly alleviate nausea and vomiting than conventional oral tablet dosage forms of ondansetron currently available.